|
1
|
Prospective randomized study of laparoscopic versus open colonic resection for adenocarcinoma.
|
Br J Surg
|
1997
|
3.10
|
|
2
|
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
|
J Natl Cancer Inst
|
1999
|
1.64
|
|
3
|
YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils.
|
Proc Assoc Am Physicians
|
1999
|
1.62
|
|
4
|
Recurrence and survival after mesorectal excision for rectal cancer.
|
Br J Surg
|
2003
|
1.61
|
|
5
|
Serum YKL-40 and colorectal cancer.
|
Br J Cancer
|
1999
|
1.57
|
|
6
|
Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group.
|
Eur J Surg Oncol
|
2000
|
1.48
|
|
7
|
Effects of the combination of blood transfusion and postoperative infectious complications on prognosis after surgery for colorectal cancer. Danish RANX05 Colorectal Cancer Study Group.
|
Br J Surg
|
2000
|
1.47
|
|
8
|
Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma.
|
Br J Cancer
|
2002
|
1.47
|
|
9
|
Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis.
|
Clin Cancer Res
|
2000
|
1.31
|
|
10
|
Effect of preoperative abstinence on poor postoperative outcome in alcohol misusers: randomised controlled trial.
|
BMJ
|
1999
|
1.29
|
|
11
|
High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.
|
Clin Cancer Res
|
2000
|
1.27
|
|
12
|
ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients.
|
Clin Chem
|
1997
|
1.26
|
|
13
|
Storage time of transfused blood and disease recurrence after colorectal cancer surgery.
|
Dis Colon Rectum
|
2001
|
1.24
|
|
14
|
Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer.
|
Br J Cancer
|
1999
|
1.24
|
|
15
|
Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer.
|
Hum Mutat
|
1997
|
1.09
|
|
16
|
Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets.
|
Scand J Clin Lab Invest
|
2002
|
1.07
|
|
17
|
Influence of major surgery on the mannan-binding lectin pathway of innate immunity.
|
Clin Exp Immunol
|
2006
|
0.99
|
|
18
|
Effect of prednisolone on the systemic response and wound healing after colonic surgery.
|
Arch Surg
|
1997
|
0.98
|
|
19
|
Mannan-binding lectin (MBL)-associated serine protease-1 (MASP-1), a serine protease associated with humoral pattern-recognition molecules: normal and acute-phase levels in serum and stoichiometry of lectin pathway components.
|
Clin Exp Immunol
|
2012
|
0.97
|
|
20
|
Postoperative morbidity among symptom-free alcohol misusers.
|
Lancet
|
1992
|
0.96
|
|
21
|
Extracellular accumulation of bioactive substances during preparation and storage of various platelet concentrates.
|
Am J Hematol
|
2001
|
0.95
|
|
22
|
[Side effects of perioperative blood transfusion--still a challenge].
|
Ugeskr Laeger
|
1993
|
0.95
|
|
23
|
Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer.
|
Clin Cancer Res
|
1998
|
0.94
|
|
24
|
Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer.
|
Scand J Gastroenterol
|
2004
|
0.94
|
|
25
|
Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay.
|
J Immunol Methods
|
1994
|
0.90
|
|
26
|
Mannan-binding lectin (MBL) and MBL-associated serine protease 2 (MASP-2) genotypes in colorectal cancer.
|
Scand J Immunol
|
2011
|
0.90
|
|
27
|
Cathepsin B/cystatin C complex levels in sera from patients with lung and colorectal cancer.
|
Biol Chem
|
2001
|
0.90
|
|
28
|
Biological variation in circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease-2 and the influence of age, gender and physical exercise.
|
Scand J Immunol
|
2007
|
0.89
|
|
29
|
The impact of storage time of transfused blood on postoperative infectious complications in rectal cancer surgery. Danish RANX05 Colorectal Cancer Study Group.
|
Scand J Gastroenterol
|
2000
|
0.89
|
|
30
|
Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein.
|
Scand J Clin Lab Invest
|
2007
|
0.89
|
|
31
|
Bioactive substances in buffy-coat-derived platelet pools stored in platelet-additive solutions.
|
Br J Haematol
|
1998
|
0.89
|
|
32
|
Impact of laparoscopic surgery on stress responses, immunofunction, and risk of infectious complications.
|
New Horiz
|
1998
|
0.88
|
|
33
|
Immune dysfunction in multiple myeloma. Reduced natural killer cell activity and increased levels of soluble interleukin-2 receptors.
|
APMIS
|
1991
|
0.88
|
|
34
|
Quality of reinfused drainage blood after total knee arthroplasty.
|
J Arthroplasty
|
1999
|
0.88
|
|
35
|
The nuclear receptors NUR77, NURR1 and NOR1 in obesity and during fat loss.
|
Int J Obes (Lond)
|
2011
|
0.88
|
|
36
|
The association between preoperative concentration of soluble vascular endothelial growth factor, perioperative blood transfusion, and survival in patients with primary colorectal cancer.
|
Eur J Surg
|
2001
|
0.87
|
|
37
|
Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1.
|
Int J Biol Markers
|
2008
|
0.87
|
|
38
|
Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients.
|
Scand J Immunol
|
2005
|
0.87
|
|
39
|
Plasma IL-6, plasma VEGF, and serum YKL-40: relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate.
|
Scand J Rheumatol
|
2007
|
0.87
|
|
40
|
Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. a validation study.
|
Eur J Cancer
|
2004
|
0.87
|
|
41
|
Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.
|
Br J Cancer
|
2009
|
0.86
|
|
42
|
Influence of open versus laparoscopically assisted colectomy on soluble vascular endothelial growth factor (sVEGF) and its soluble receptor 1 (sVEGFR1).
|
Inflamm Res
|
2005
|
0.84
|
|
43
|
Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay.
|
Int J Biol Markers
|
2003
|
0.83
|
|
44
|
Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
|
Gynecol Oncol
|
2001
|
0.83
|
|
45
|
Investigation of tissue inhibitor of metalloproteinases 1 in plasma from colorectal cancer patients and blood donors by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
|
Int J Biol Markers
|
2007
|
0.83
|
|
46
|
A randomized pilot study on single-port versus conventional laparoscopic rectal surgery: effects on postoperative pain and the stress response to surgery.
|
Tech Coloproctol
|
2014
|
0.83
|
|
47
|
DNA ploidy in colorectal cancer, heterogeneity within and between tumors and relation to survival.
|
Cytometry
|
1999
|
0.82
|
|
48
|
Levels of tissue inhibitor of metalloproteinases-1 in blood transfusion components.
|
Scand J Clin Lab Invest
|
2002
|
0.82
|
|
49
|
Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer.
|
Ann Oncol
|
2010
|
0.82
|
|
50
|
Duration of postoperative immunosuppression assessed by repeated delayed type hypersensitivity skin tests.
|
Eur Surg Res
|
1992
|
0.82
|
|
51
|
Studies on mast cells and histamine release in psoriasis: the effect of ranitidine.
|
Acta Derm Venereol
|
1998
|
0.81
|
|
52
|
Improved vaccination response during ranitidine treatment, and increased plasma histamine concentrations, in patients with B cell chronic lymphocytic leukemia.
|
Leukemia
|
1995
|
0.81
|
|
53
|
The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer.
|
APMIS
|
1999
|
0.81
|
|
54
|
Cardiovascular and respiratory changes and convalescence in laparoscopic colonic surgery: comparison between carbon dioxide pneumoperitoneum and gasless laparoscopy.
|
Arch Surg
|
1999
|
0.81
|
|
55
|
Blood loss and transfusion after total mesorectal excision and conventional rectal cancer surgery.
|
Colorectal Dis
|
2004
|
0.81
|
|
56
|
A randomized controlled study of the effect of bedside leucocyte depletion on the immunosuppressive effect of whole blood transfusion in patients undergoing elective colorectal surgery.
|
Br J Surg
|
1996
|
0.80
|
|
57
|
A consistent shift in VEGF determinations between two different ELISA batch numbers.
|
Br J Cancer
|
2003
|
0.80
|
|
58
|
Immunomodulating effect of blood transfusion: is storage time important?
|
Vox Sang
|
1998
|
0.80
|
|
59
|
Soluble urokinase plasminogen activator receptor in blood transfusion components.
|
Transfus Med
|
2004
|
0.79
|
|
60
|
The role of tissue factor in colorectal cancer.
|
Eur J Surg Oncol
|
2003
|
0.79
|
|
61
|
Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer.
|
Scand J Clin Lab Invest
|
2007
|
0.79
|
|
62
|
Ranitidine reduces postoperative interleukin-6 induced C-reactive protein synthesis.
|
J Am Coll Surg
|
1995
|
0.78
|
|
63
|
Changes in plasma TIMP-1 levels after resection for primary colorectal cancer.
|
Anticancer Res
|
2009
|
0.78
|
|
64
|
The effect of ranitidine on postoperative infectious complications following emergency colorectal surgery: a randomized, placebo-controlled, double-blind trial.
|
Inflamm Res
|
1998
|
0.78
|
|
65
|
Accumulation of the neutrophil-derived protein YKL-40 during storage of various blood components.
|
Inflamm Res
|
2001
|
0.78
|
|
66
|
Bacterial antigen induced release of soluble vascular endothelial growth factor (VEGF) and VEGFR1 before and after surgery.
|
Scand J Clin Lab Invest
|
2005
|
0.77
|
|
67
|
[Significance of vascular endothelial growth factor--VEGF--in tumor angiogenesis. Therapeutic possibilities in solid tumors].
|
Ugeskr Laeger
|
2000
|
0.77
|
|
68
|
Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer.
|
Int J Biol Markers
|
2005
|
0.77
|
|
69
|
Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.
|
Int J Biol Markers
|
2005
|
0.77
|
|
70
|
Identifying sources and estimating glandular output of salivary TIMP-1.
|
Scand J Clin Lab Invest
|
2008
|
0.77
|
|
71
|
Loss of ELISA specificity due to biotinylation of monoclonal antibodies.
|
J Immunol Methods
|
2000
|
0.77
|
|
72
|
Cytokeratin-positive cells in preoperative peripheral blood and bone marrow aspirates of patients with colorectal cancer.
|
Scand J Clin Lab Invest
|
2002
|
0.76
|
|
73
|
Levels of tissue inhibitor of metalloproteinases 1 in plasma and urine from patients with bladder cancer.
|
Int J Biol Markers
|
2006
|
0.76
|
|
74
|
Codeine-induced histamine release in intact human skin monitored by skin microdialysis technique: comparison of intradermal injections with an atraumatic intraprobe drug delivery system.
|
Clin Exp Allergy
|
1995
|
0.75
|
|
75
|
Identification of alternatively spliced TIMP-1 mRNA in cancer cell lines and colon cancer tissue.
|
Mol Oncol
|
2007
|
0.75
|
|
76
|
Investigation of tissue inhibitor of metalloproteinases 1 in plasma from colorectal cancer patients and blood donors by surface-enhanced laser desorption/ionization time-of-flight mass spectrometryscopy.
|
Int J Biol Markers
|
2017
|
0.75
|
|
77
|
[Can detection of cancer cells in bone marrow and peripheral blood be used in diagnosis and patient monitoring?].
|
Ugeskr Laeger
|
1998
|
0.75
|
|
78
|
Reduction of bioactive substances in stored donor blood: prestorage versus bedside leucofiltration.
|
Eur J Haematol
|
1999
|
0.75
|
|
79
|
[Leukocyte filtration in elective colorectal surgery. Reduced transfusion associated immunosuppression after bedside procedures].
|
Ugeskr Laeger
|
1997
|
0.75
|
|
80
|
Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patients.
|
Clin Chem
|
1999
|
0.75
|
|
81
|
[Aortofemoral bypass and extensive profunda-plasty in combined arterial occlusive disease of the pelvic-femoral type--a stage oriented analysis].
|
Vasa
|
1993
|
0.75
|
|
82
|
[The effect of prednisolone on the systemic response and wound healing after colonic surgery].
|
Ugeskr Laeger
|
1998
|
0.75
|
|
83
|
Levels of tissue inhibitor of metalloproteinases 1 in plasma and urine from patients with bladder cancer.
|
Int J Biol Markers
|
2017
|
0.75
|
|
84
|
Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.
|
Int J Biol Markers
|
2017
|
0.75
|
|
85
|
Prestorage and bedside leucofiltration of whole blood modulates storage-time-dependent suppression of in vitro TNFalpha release.
|
Br J Haematol
|
1999
|
0.75
|
|
86
|
Prestorage leukofiltration of whole blood and SAGM blood prevents extracellular bioactive substance accumulation.
|
Inflamm Res
|
1999
|
0.75
|
|
87
|
Systemic high-dose ranitidine in the treatment of psoriasis: an open prospective clinical trial.
|
Br J Dermatol
|
1995
|
0.75
|
|
88
|
Ranitidine for improvement of treatment-resistant psoriasis.
|
Arch Dermatol
|
1991
|
0.75
|
|
89
|
The use of the CELLection kit in the isolation of carcinoma cells from mononuclear cell suspensions.
|
J Immunol Methods
|
2000
|
0.75
|
|
90
|
Immunoglobulin and enzyme-conjugated dextran polymers enhance u-PAR staining intensity of carcinoma cells in peripheral blood smears.
|
J Histochem Cytochem
|
1999
|
0.75
|
|
91
|
Various functions of PBMC from colon cancer patients are not decreased compared to healthy blood donors.
|
Cancer Biother Radiopharm
|
1997
|
0.75
|
|
92
|
Decreased tetranectin in multiple myeloma.
|
Am J Hematol
|
1990
|
0.75
|
|
93
|
[Histamine-2 blockade in skin disease].
|
Ugeskr Laeger
|
1989
|
0.75
|
|
94
|
[Urinary incontinence. A study of occurrence in the municipality of Sund].
|
Tidsskr Nor Laegeforen
|
1989
|
0.75
|
|
95
|
IgE levels in surgery: effect of ranitidine and prednisolone.
|
Allergy
|
1999
|
0.75
|
|
96
|
[Immunologic consequences of surgery, anesthesia and blood transfusion. Surgical immunosuppression].
|
Ugeskr Laeger
|
1989
|
0.75
|
|
97
|
Possible effect of histamine-2 receptor blockade on the antitumour response to interleukin-2.
|
Eur J Cancer
|
1995
|
0.75
|
|
98
|
[Histamine-2 blockade in psoriasis].
|
Ugeskr Laeger
|
1991
|
0.75
|
|
99
|
[Postoperative morbidity among alcohol abusers].
|
Ugeskr Laeger
|
1994
|
0.75
|
|
100
|
Effect of heating on extracellular bioactive substances in stored human blood: in vitro study.
|
J Trauma
|
1997
|
0.75
|